{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:23:10Z","timestamp":1785777790639,"version":"3.56.0"},"reference-count":85,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mesothelioma comprises a group of rare cancers arising from the mesothelium of the pleura, peritoneum, tunica vaginalis testis and pericardium. Mesothelioma is generally associated with asbestos exposure and has a dismal prognosis, with few therapeutic options. Several next generation sequencing (NGS) experiments have been performed on mesothelioma arising at different sites. These studies highlight a genomic landscape mainly characterized by a high prevalence (&gt;20%) of genomic aberrations leading to functional losses in oncosuppressor genes such as BAP1, CDKN2A, NF2, SETD2 and TP53. Nevertheless, to date, evidence of the effect of targeting these alterations with specific drugs is lacking. Conversely, 1\u20132% of mesothelioma might harbor activating mutations in oncogenes with specifically approved drugs. The goal of this review is to summarize NGS applications in mesothelioma and to provide insights into target therapy of mesothelioma guided by NGS.<\/jats:p>","DOI":"10.3390\/cancers15245716","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T03:48:41Z","timestamp":1701834521000},"page":"5716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack"],"prefix":"10.3390","volume":"15","author":[{"given":"Luigi","family":"Cerbone","sequence":"first","affiliation":[{"name":"Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Orecchia","sequence":"additional","affiliation":[{"name":"Molecular Pathology Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-5778","authenticated-orcid":false,"given":"Pietro","family":"Bertino","sequence":"additional","affiliation":[{"name":"Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-7340","authenticated-orcid":false,"given":"Sara","family":"Delfanti","sequence":"additional","affiliation":[{"name":"Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina Maria","family":"de Angelis","sequence":"additional","affiliation":[{"name":"Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[{"name":"Mesothelioma Unit, SS Antonio e and Biagio Hospital, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1470-2045(22)00269-8","article-title":"The silent malignant mesothelioma epidemics: A call to action","volume":"23","author":"Rasko","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17476348.2020.1714441","article-title":"Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: Recent advances and new perspectives","volume":"14","author":"Genova","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Florent, L., Saby, C., Slimano, F., and Morjani, H. (2023). BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge. Cancers, 15.","DOI":"10.3390\/cancers15092607"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cho, S.M., Esmail, A., Raza, A., Dacha, S., and Abdelrahim, M. (2022). Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14112641"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Borea, F., Franczak, M.A., Garcia, M., Perrino, M., Cordua, N., Smolenski, R.T., Peters, G.J., Dziadziuszko, R., Santoro, A., and Zucali, P.A. (2023). Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119165"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Monica","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic Landscape of Malignant Mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000507373","article-title":"Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas","volume":"87","author":"Campanella","year":"2020","journal-title":"Pathobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Milbury, C.A., Creeden, J., Yip, W.-K., Smith, D.L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., and Skoletsky, J. (2022). Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264138"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","article-title":"Molecular Characterization of Peritoneal Mesotheliomas","volume":"17","author":"Offin","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jtho.2022.08.017","article-title":"Multimodality Therapy in Patients With Primary Pericardial Mesothelioma","volume":"17","author":"Offin","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.modpat.2023.100237","article-title":"Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma","volume":"36","author":"Schaefer","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/his.14669","article-title":"Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis","volume":"81","author":"Anderson","year":"2022","journal-title":"Histopathology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/sj.onc.1202737","article-title":"Tissue-specific alternative splicing in the human INK4a\/ARF cell cycle regulatory locus","volume":"18","author":"Robertson","year":"1999","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_31","first-page":"100231","article-title":"Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients with Merlin-Stratified Pleural Mesothelioma: COMMAND\u2014A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: Not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102101","DOI":"10.1016\/j.ctrv.2020.102101","article-title":"Is DNA repair a potential target for effective therapies against malignant mesothelioma?","volume":"90","author":"Roca","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2021.12.023","article-title":"Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment","volume":"163","author":"Sculco","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2022.40.16_suppl.3122","article-title":"Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms","volume":"40","author":"George","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.cllc.2020.07.014","article-title":"A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non\u2013small-cell Lung Cancer and\/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design","volume":"22","author":"Passiglia","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.xcrm.2022.100915","article-title":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma","volume":"4","author":"Pandey","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11523-022-00900-2","article-title":"Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP","volume":"17","author":"Dubois","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1369\/0022155414561498","article-title":"Understanding the roles of FAK in cancer: Inhibitors, genetic models, and new insights","volume":"63","author":"Yoon","year":"2015","journal-title":"J. Histochem. Cytochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","article-title":"Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma","volume":"19","author":"Kanteti","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jtho.2023.09.680","article-title":"P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP\/TEAD Inhibitor in Patients with Advanced Mesothelioma","volume":"18","author":"Yap","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_60","first-page":"2589","article-title":"Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma","volume":"34","author":"Varesano","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jtho.2017.03.015","article-title":"FISH Analysis of Crizotinib Target Genes ROS1\/ALK\/MET in Malignant Mesothelioma","volume":"12","author":"Salvi","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.05.019","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"153772","DOI":"10.1016\/j.prp.2022.153772","article-title":"Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!","volume":"231","author":"Cordier","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1753466620935770","DOI":"10.1177\/1753466620935770","article-title":"Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: A case report","volume":"14","author":"Hu","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/PO.21.00184","article-title":"STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy","volume":"5","author":"Gerthofer","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e29544","DOI":"10.1002\/pbc.29544","article-title":"Mesothelioma with ALK gene mutations in two pediatric patients: Clinical course and outcome","volume":"69","author":"Kimpo","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_68","first-page":"1","article-title":"STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment","volume":"3","author":"Gradhand","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e13631","DOI":"10.15252\/emmm.202013631","article-title":"KRAS signaling in malignant pleural mesothelioma","volume":"14","author":"Marazioti","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Trassl, L., and Stathopoulos, G.T. (2022). KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player. Cancers, 14.","DOI":"10.3390\/cancers14174303"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jtcvs.2013.08.035","article-title":"Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro","volume":"147","author":"You","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Li, H., Lui, N., Cheng, T., Tseng, H.-H.K., Yue, D., Giroux-Leprieur, E., Do, H.T., Sheng, Q., Jin, J.Q., and Luh, T.W. (2013). Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057346"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","article-title":"Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma","volume":"15","author":"Meerang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition","volume":"24","author":"Badhai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Abbott, D.M., Bortolotto, C., Benvenuti, S., Lancia, A., Filippi, A.R., and Stella, G.M. (2020). Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers, 12.","DOI":"10.3390\/cancers12051186"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.ctrv.2022.102455","article-title":"Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments","volume":"110","author":"Stacchiotti","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2589-7500(21)00104-7","article-title":"The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: A retrospective study","volume":"3","author":"Zauderer","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e000683","DOI":"10.1136\/esmoopen-2020-000683","article-title":"New emerging targets in cancer immunotherapy: The role of VISTA","volume":"4","author":"Tagliamento","year":"2020","journal-title":"ESMO Open"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:33:52Z","timestamp":1760132032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":85,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245716"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245716","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}